Patient and transplantation characteristics
| . | Patient 1 . | Patient 2 . | Patient 3 . | Patient 4 . | Patient 5 . |
|---|---|---|---|---|---|
| Age at transplantation | 7 y 3 mo | 1 y 7 mo | 1 y 10 mo | 1 y 2 mo | 7 y 8 mo |
| Disease | AML refractory to chemotherapy | AML refractory to chemotherapy | AML; relapse after completion of fourth chemotherapy cycle | High-risk infant ALL; on-treatment myeloid relapse | AML refractory to chemotherapy |
| Cytogenetics | Monosomy 7 | t(9;11) | t(9;11) | t(4;11) | t(8;21) |
| Disease status at transplantation | 65% blasts | 90% blasts | Prolonged aplasia after salvage chemotherapy | MRD+(0.65%) | 30% blasts |
| Conditioning | Fludarabine, treosulfan, thiotepa | Fludarabine, busulfan | Treosulfan | Treosulfan, thiotepa | Busulfan, cyclophosphamide |
| HLA matching (A, B, C, DRB) | 8 of 8 | 7 of 8 (DRB1 mismatch) | 8 of 8 | 6 of 8 (HLA-B and -C mismatch) | 7 of 8 (HLA-C mismatch) |
| Other HLA loci (DQB, DPB) | DQB1 match, DPB1 mismatch at 1 allele | DQB1 mismatch at 1 allele, DPB1 mismatch at 1 allele | DQB1 match, DPB1 mismatch for both loci | DQB1 match, DPB1 mismatch at 1 allele | DQB1 mismatch, DPB1 mismatch |
| GVHD prophylaxis | Ciclosporin | Ciclosporin | Ciclosporin | Ciclosporin | Ciclosporin |
| Total nucleated cell dose, ×107/kg | 8.01 | 14.7 | 7.65 | 18.9 | 4.6 |
| CD34+ cell dose, ×105/kg | 1.5 | 3.5 | 5.7 | 6.9 | 1.1 |
| No. of days of granulocytes | 12 (day −6, −5, −4, −1, 0, +1, +2, +3, +8, +9, +10, +11) | 13 (day −10, −9, −6, −5, −3, −2, +2, +3, +4, +8, +9 +10, +14) | 10 (day +1, +2, +3, +4, +5, +8, +9, +10, +11, +12) | 11 (day −2, −1, 0, +1, +2, +5, +6, +7, +8, +9, +12) | 10 (day +0, +1, +2, +3, +4, +7, +8, +9, +10, +11) |
| Reason for granulocytes | Fungal chest infection | Fungal chest infection | Bacteraemia and meningitis | Fungal chest infection | Fungal chest infection |
| . | Patient 1 . | Patient 2 . | Patient 3 . | Patient 4 . | Patient 5 . |
|---|---|---|---|---|---|
| Age at transplantation | 7 y 3 mo | 1 y 7 mo | 1 y 10 mo | 1 y 2 mo | 7 y 8 mo |
| Disease | AML refractory to chemotherapy | AML refractory to chemotherapy | AML; relapse after completion of fourth chemotherapy cycle | High-risk infant ALL; on-treatment myeloid relapse | AML refractory to chemotherapy |
| Cytogenetics | Monosomy 7 | t(9;11) | t(9;11) | t(4;11) | t(8;21) |
| Disease status at transplantation | 65% blasts | 90% blasts | Prolonged aplasia after salvage chemotherapy | MRD+(0.65%) | 30% blasts |
| Conditioning | Fludarabine, treosulfan, thiotepa | Fludarabine, busulfan | Treosulfan | Treosulfan, thiotepa | Busulfan, cyclophosphamide |
| HLA matching (A, B, C, DRB) | 8 of 8 | 7 of 8 (DRB1 mismatch) | 8 of 8 | 6 of 8 (HLA-B and -C mismatch) | 7 of 8 (HLA-C mismatch) |
| Other HLA loci (DQB, DPB) | DQB1 match, DPB1 mismatch at 1 allele | DQB1 mismatch at 1 allele, DPB1 mismatch at 1 allele | DQB1 match, DPB1 mismatch for both loci | DQB1 match, DPB1 mismatch at 1 allele | DQB1 mismatch, DPB1 mismatch |
| GVHD prophylaxis | Ciclosporin | Ciclosporin | Ciclosporin | Ciclosporin | Ciclosporin |
| Total nucleated cell dose, ×107/kg | 8.01 | 14.7 | 7.65 | 18.9 | 4.6 |
| CD34+ cell dose, ×105/kg | 1.5 | 3.5 | 5.7 | 6.9 | 1.1 |
| No. of days of granulocytes | 12 (day −6, −5, −4, −1, 0, +1, +2, +3, +8, +9, +10, +11) | 13 (day −10, −9, −6, −5, −3, −2, +2, +3, +4, +8, +9 +10, +14) | 10 (day +1, +2, +3, +4, +5, +8, +9, +10, +11, +12) | 11 (day −2, −1, 0, +1, +2, +5, +6, +7, +8, +9, +12) | 10 (day +0, +1, +2, +3, +4, +7, +8, +9, +10, +11) |
| Reason for granulocytes | Fungal chest infection | Fungal chest infection | Bacteraemia and meningitis | Fungal chest infection | Fungal chest infection |